Danielle Bucco

Patients with renal cell carcinoma have seen a change in standard of care as novel therapies and combinations are quickly approved, says Toni K. Choueiri, MD.

The frontline treatment of patients with ovarian cancer may potentially change in the near future, with targeted and immunotherapy strategies showing promising signals of activity.

While PARP inhibitors have demonstrated success in ovarian cancer previously, they are finally impacting the treatment paradigm for patients with <em>BRCA</em>-positive breast cancers, according to Nadine M. Tung, MD.&nbsp;

While relapsed/refractory mantle cell lymphoma (MCL) is considered an aggressive disease, new findings show patients may benefit from adding chimeric antigen receptor T-cell therapy to their treatment regimen. ZUMA-2, a currently ongoing trial, aims to understand the potential benefits with axicabtagene ciloleucel, an&nbsp;anti-CD19 CAR T-cell product, for&nbsp;patients with relapsed/refractory MCL.

According to Neil E. Kay, MD, novel agents,&nbsp;such as&nbsp;ibrutinib (Imbruvica), venetoclax (Venclexta), idelalisib (Zydelig), and acalabrutinib (Calquence), are revolutionizing treatment for patients with chronic&nbsp;lymphocytic leukemia. However, the best way to sequence these agents to maximize the benefit to patients is still unclear.

David O&#39;Malley, MD,&nbsp;discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

One of the most exciting advancements in the lymphoma community has been the FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta) for patients with non-Hodgkin lymphoma&nbsp;in October 2017.

Several combinations are being investigated for patients with chronic lymphocytic leukemia, said Ian W. Flinn, MD, citing numerous ongoing trials presented at the 2017 ASH Annual Meeting.

Brad S. Kahl, MD,&nbsp;discusses the latest data for ibrutinib and highlighted emerging treatments in MCL.<br /> &nbsp;

Updates from the KEYNOTE-189 and IMpower150 trials demonstrated the significant impact of adding&nbsp;immunotherapy to treatment regimens for patients with non&ndash;small cell lung cancer.

Treatment with the&nbsp;CD19-targeted chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel, formally known as JCAR017) demonstrated&nbsp;a complete response rate of 63% and an&nbsp;objective response rate of 81%&nbsp;in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD,&nbsp;shares more insight on acalabrutinib and ibrutinib&rsquo;s efficacy in patients with MCL and highlights emerging novel strategies in the treatment landscape.

Rebecca C. Arend, MD,&nbsp;discusses novel combinations being investigated for the treatment of patients with ovarian cancer.

Kathleen Moore, MD,&nbsp;discusses combination strategies with immunotherapy for patients with ovarian cancer during the&nbsp;2018 Society of Gynecologic Oncology Annual Winter Meeting.<br /> &nbsp;

Rana R. McKay, MD,&nbsp;discusses the evolving management of patients with advanced RCC, specifically the future of combinations with immunotherapy regimens.

Narendranath Epperla, MD,&nbsp;discusses the phase III GALLIUM trial, and the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Arjun Balar, MD,&nbsp;discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.

Michael A. Postow, MD, discusses the evolution of combination therapies for patients with melanoma.

CMB305, an immunotherapy regimen that generates and expands anti&ndash;NY-ESO-1 T cells, demonstrated a favorable survival rate compared with other approved agents for recurrent soft tissue sarcoma, according to results presented at the 2017 ASCO Annual Meeting.

Tim G. Larson, MD, discusses&nbsp;emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) CRC and highlights some of the identified molecular mutations in patients with CRC.

A. David McCollum, MD, discusses&nbsp;the optimal management of CRC in the first-line setting and the ongoing research with checkpoint inhibitors designed to benefit larger groups of patients.<br /> &nbsp;

Carlos Becerra, MD, discusses&nbsp;the current management and emerging therapies for patients with pancreatic cancer.

Lajos Pusztai, MD,&nbsp;discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.<br /> &nbsp;

George R. Blumenschein, MD,&nbsp;discusses the current treatment landscape for patients with squamous cell lung cancer.

Adam Waxman, MD,&nbsp;discusses emerging regimens for patients with multiple myeloma.<br /> &nbsp;

Johanna Bendell, MD, discusses&nbsp; the current and emerging treatment landscape of immunotherapy for patients with CRC.

For patients with metastatic melanoma in particular, immune checkpoint inhibitors were a great advancement in therapeutics. Since then, investigators have focused on ways to improve on treatment with these agents, and one potential method is through manipulation of the gut microbiome.

In an interview, Jonathan E. Rosenberg, MD, discusses the guidelines and their significance for the treatment of patients with muscle-invasive bladder cancer.

Researchers are seeking prognostic biomarkers for response to treatment with adjuvant sorafenib (Nexavar) in patients with hepatocellular carcinoma, according to a presentation during the&nbsp;2017 International Liver Cancer Association Annual Conference in Seoul, South Korea.

Researchers in the Perelman School of Medicine at the University of Pennsylvania evaluated the genetic profiles of 160 breast and ovarian cancers associated with germline mutations in&nbsp;<em>BRCA1 </em>and <em>BRCA2&nbsp;</em>and determined that there is a relationship between the genetics of <em>BRCA 1/2 </em>mutations and the risk of resistance to platinum-based chemotherapy.&nbsp;